

DORSET MEDICINES ADVISORY GROUP Recommendation Summary

Formerly the Bournemouth, Dorset and Poole Health Technologies Forum, DMAG represents the four provider Trusts and GPs within the Clinical Commissioning Group (CCG). It provides recommendations to the CCG on the prescribing and commissioning of medicines.

Summary of recommendations considered at a meeting of the group on 17th January 2017. Formulary entries and associated documents can be accessed at www.dorsetformulary.nhs.uk.

PRODUCT	DECISION	COMMENTS
1. Products re-categorised		
2. New requests		
Polymen [®]	Approved	Polymem [®] to be included on the Pan Dorset Formulary as “Red” with specialist prescribing
Zetuvit Plus [®]	Approved	Zetuvit Plus [®] to become 1 st choice Super Absorbent Dressing on the pan Dorset Formulary with a “Green” traffic light status.
KerraMax Care [®]	Approved	KerraMax Care [®] to become 2 nd choice Super Absorbent Dressing on the pan Dorset Formulary with a “Green” traffic light status.

PRODUCT	DECISION	COMMENTS
Biatain Silicone ®	Approved	Biatain Silicone ® to be added as silicone foam on the pan Dorset Formulary with a “Green “traffic light status.
Urgo Absorb®	Approved	Urgo Absorb® to be added as silicone foam on the pan Dorset Formulary with a “Green “traffic light status.
Insulin Degludec with Liraglutide (Xultophy®)	Approved	Insulin Degludec with Liraglutide (Xultophy®) to be added to the pan Dorset Formulary with an “AMBER” traffic light classification.
3. Products considered by NICE		
Ticagrelor	Approved	The commissioning statement to support the use of Ticagrelor for preventing atherothrombotic events after myocardial infarction in accordance with NICE TA 420 was approved with an “AMBER” traffic light classification.
Apremilast	Approved	Commissioning statement to support the use of Apremilast in Plaque Psoriasis in accordance with NICE TA 419 (Apremilast for treating moderate to severe plaque psoriasis) was approved with a “RED” traffic light classification.
4. Miscellaneous recommendations by DMAG		
Commissioning statement to support the use of SGLT2 inhibitors in type 2 diabetes	Approved	Review of the commissioning statement to support the use of SGLT2 inhibitors in type 2 diabetes to include NICE TA 418 (Dapagliflozin in triple therapy for treating type 2 diabetes) was approved
Shared Care Guidelines for the use of Thiopurines	Approved	Shared Care Guideline for the use of Thiopurines in Adults with inflammatory bowel disease (IBD) was approved.

PRODUCT	DECISION	COMMENTS
Acne Vulgaris Pathway	Approved	Acne Vulgaris Pathway was approved to be added to website and pan Dorset Formulary
Toujeo®	Approved	Pan Dorset Formulary entry to be amended to include “specialists” to reflect the inclusion of Diabetes Nurses Specialists and the wording around dosage to read “patients requiring greater than 100 units” was approved.
Dermacool®	Approved	All strengths of Dermacool to be added to existing pan Dorset formulary entry
Calcium Channel Blockers	Approved	Formulary choices of calcium channel blockers (CCBs) for treating hypertension have been updated. The formulary choices are now as follows: 1 st choice Amlodipine 2 nd choice Lercanidipine (previously Felodipine) 3 rd choice Lacidipine 4 th choice Felodipine MR Option choices agreed for new initiations, existing patients will not be switched unless clinically appropriate
5. Further Assessment / Evidence Required		
Botulinum Toxin for Achalasia	Deferred (Until August 2017)	DMAG have approved Botulinum toxin for Achalasia, however this drug cannot go on formulary for this indication pending the criteria based access policy being reviewed, the due date for this is August 2017 and work has commenced to address this.
Shared Care Guidelines for Methotrexate in Psoriasis	Approval Pending	Depending on clarification on areas of responsibilities and associated actions the shared care guidelines for Methotrexate in Psoriasis are approved and are to be re-submitted to the DMAG once actions have been completed for noting only.

PRODUCT	DECISION	COMMENTS
6. Expired Documents Reviewed		
Statement from the pan-Dorset Cardiology Working Group on the use of Metolazone	Approved	Expired document to be replaced on website and pan Dorset Formulary with reviewed version
Shared care guideline for the use of Sacubitril Valsartan for treating symptomatic chronic heart failure with reduced ejection fraction	Approved	Expired document to be replaced on website and pan Dorset Formulary with reviewed version
Commissioning statement on the use of Ivabradine in chronic heart failure	Approved	Expired document to be replaced on website and pan Dorset Formulary with reviewed version
Shared Care Guideline for prescribing Ivabradine (Procoralan®) as a monotherapy rate-limiting agent in angina	Approved	Expired document to be replaced on website and pan Dorset Formulary with reviewed version
Shared care guideline for prescribing Ivabradine (Procoralan®) as treatment for chronic heart failure	Approved	Expired document to be replaced on website and pan Dorset Formulary with reviewed version
Commissioning statement on the use of Bivalirudin (Angiox®) for the treatment of st-segment-elevation myocardial infarction	Approved	Expired document to be replaced on website and pan Dorset Formulary with reviewed version
Shared care guideline for prescribing Ranolazine (Ranexa®) for the treatment of symptomatic stable angina pectoris.	Approved	Expired document to be replaced on website and pan Dorset Formulary with reviewed version
Policy for the use of digoxin specific antibody (Digifab®)	Approved	Expired document to be replaced on website and pan Dorset Formulary with reviewed version
Commissioning statement on Anoro® Ellipta® (Umeclidinium	Approved	Expired document to be replaced on website and pan Dorset Formulary with reviewed version

PRODUCT	DECISION	COMMENTS
Bromide + Vilanterol) as maintenance bronchodilator treatment for chronic obstructive pulmonary disease (copd)		
Commissioning statement on Eklira Genuair® (Aclidinium Bromide) as maintenance bronchodilator treatment for chronic obstructive pulmonary disease (copd)	Approved	Expired document to be replaced on website and pan Dorset Formulary with reviewed version
Commissioning statement for the use of growth hormone in adults and children	Approved	Expired document to be replaced on website and pan Dorset Formulary with reviewed version

Classification of products:

'RED' drugs for hospital use only

'AMBER with shared care' drugs suitable for use with shared care arrangements

'AMBER' drugs suitable for use without shared care arrangements

'GREEN' drugs suitable for prescribing in primary and secondary care

'Not Recommended' – drugs not recommended for use in Dorset

The new traffic light system can be found on the Dorset CCG internet at: [Dorset CCG - Traffic light scheme](#)